Six novel antimycotics

American Journal of Clinical Dermatology

Volumn 3, Issue 2, 2002, Pages 71-81

  Rubin, Adam I ^a   Bagheri, Bita ^a   Scher, Richard K ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[4 (2,4 DICHLOROPHENYL) 1,3 DITHIOLAN 2 YLIDENE] 1 IMIDAZOLYL ACETONITRILE; [4 (2,4 DICHLOROPHENYL) 1,3 DITHIOLAN 2 YLIDENE](1 IMIDAZOLYL)ACETONITRILE; AMPHOTERICIN B; ANTIFUNGAL AGENT; BIFONAZOLE; BUTENAFINE; CLOTRIMAZOLE; EBERCONAZOLE; FLUCONAZOLE; FLUCYTOSINE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; LANOCONAZOLE; NAFTIFINE; NND 3138; RILOPIROX; TERBINAFINE; TOLNAFTATE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG MECHANISM; ERYTHEMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SEBORRHEIC DERMATITIS; SKIN DISEASE; TINEA; TINEA CORPORIS; TINEA CRURIS; TINEA PEDIS; TINEA VERSICOLOR; WOUND HEALING;

ANIMALS; ANTIFUNGAL AGENTS; DERMATOMYCOSES; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE;

EID: 0036200264     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200203020-00001     Document Type: Review

References (69)

1. Studies for the elucidation of the mode of action of the antimycotic hydroxypyridone compound, rilopirox
2. Inhibition of Candida albicans adhesiveness to human buccal and vaginal cells by sub-inhibitory concentrations of rilopirox
3. Rilopirox: A new hydroxypyridone antifungal with fungicidal properties
4. In vitro susceptibility testing of Malassezia furfur against rilopirox
5. In vitro activity of rilopirox against fluconazole-susceptible and fluconazole-resistant Candida isolates from patients with HIV infection
6. The in vitro properties of a new hydroxypyridone antimycotic rilopirox, with special reference to its anti-Candida activity
7. Effects of rilopirox on rabbit blastocysts in a protein-free in vitro culture under different culture conditions
8. Ultrastructural investigations of Candida albicans after in vitro treatment with the new fungicidal agent rilopirox
9. Studies on the antifungal activity of the new imidazole antimycotic lanoconazole in infected sites: Distribution in the skin and in vitro activity in the presence of stratum corneum
10. Update on topical therapy for superficial fungal infections: Focus on butenafine
11. P450 inhibitors of use in medical treatment: Focus on mechanisms of action
12. Therapeutic efficacy of lanoconazole ointment in guinea pig model of tinea pedis, in comparison with that of cream preparations
13. Therapeutic efficacy of lanoconazole, a new imidazole antimycotic agent, for experimental cutaneous candidiasis in guinea pigs
14. Short-term topical therapy of experimental tinea pedis in guinea pigs with lanoconazole, a new imidazole antimycotic agent
15. Therapeutic efficacy of lanoconazole ointment in guinea pig model of tinea corporis, a comparative study with ointment and cream preparations
16. Allergic contact dermatitis from lanoconazole
17. Contact dermatitis from lanoconazole
18. Allergic contact dermatitis due to lanoconazole with no cross-reactivity to other imidazoles
19. In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent
20. Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of Candida albicans and Aspergillus fumigatus infections
21. Inhibition of sterol 14 alpha-demethylation of Candida albicans with NND-502: A novel optically active imidazole antimycotic agent
22. The antifungal agent butenafine manifests anti-inflammatory activity in vivo
23. Butenafine 1% cream in the treatment of tinea cruris: A multicenter, vehicle-controlled, double-blind trial
24. Anti-trichophyton mentagrophytes activity and percutaneous permeation of butenafine in guinea pigs
25. Effects of butenafine hydrochloride, a new benzylamine derivative, on experimental tinea pedis in guinea pigs
26. Studies on the antifungal mechanism of butenafine hydrochloride, I: Inhibition of qualene epoxidation and damaging of cell membranes in Sporothrix schenckii cells
27. Studies on the antifungal mechanism of butenafine hydrochloride, II: Comparison in the response to drug treatment between a wild-type strain and tolciclate-resistant mutant of Sporothrix schenckii cells
28. Mechanisms of action of systemic antifungal agents
29. Terbinafine: Mode of action and properties of the squalene epoxidase inhibition
30. Two mechanisms of butenafine action in Candida albicans
31. Butenafine
32. Effects of butenafine hydrochloride, a new benzylamine derivative, on experimental dermatophytosis in guinea pigs
33. Topical treatment with butenafine significantly lowers relapse rate in an interdigital tinea pedis model in guinea pigs
34. One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: A multicenter, double-blind trial
35. Treatment of interdigital tinea pedis with a 4-week once-daily regimen of butenafine hydrochloride 1% cream
36. A randomized trial to assess once-daily topical treatment of tinea corporis with butenafine, a new antifungal agent
37. Anti-inflammatory activity of antifungal preparations
38. Skin safety study of KP-363, a new antifungal agent, in healthy volunteers: Comparative study with other antifungals
39. In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole
40. Topical treatment of tinea corporis and tinea cruris with eberconazole (WAS 2160) cream 1% and 2%: A phase II dose-finding pilot study
41. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Synthesis and SAR
42. Voriconazole: A new triazole antifungal
43. Current and emerging azole antifungal agents
44. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Pharmacokinetics in man
45. Aspergillus meningitis: Diagnosis by non-culture-based microbiological methods and management
46. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Disposition in man
47. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei
48. Effect of grapefruit juice on serum voriconazole concentrations in the mouse
49. Skull base osteitis following fungal sinusitis
50. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Antifungal activity and selectivity in vitro
51. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
52. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B
53. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
54. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients
55. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens
56. Use of voriconazole in treatment of Scedosporium apiospermum infection: Case report
57. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease
58. The search for new triazole antifungal agents
59. International surveillance of blood stream infections due to Candida species in the European SENTRY program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents: SENTRY Participant Group (Europe)
60. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis (OPC)
61. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS
62. Antifungal and surgical treatment of invasive aspergillosis: Review of 2,121 published cases
63. Invasive central nervous system aspergillosis: Cure with liposomal amphotericin B, itraconazole, and radical surgery: Case report and review of the literature
64. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Clinical efficacy in chronic invasive aspergillosis-interim analysis results
65. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Clinical efficacy in acute invasive aspergillosis
66. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery
67. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia
68. Microgranulomatous aspergillosis in a patient with chronic granulomatous disease: Cure with voriconazole